Call for Research Ethics Board Panelists for the September 10, 2020 Health Canada Engagement Session


On May 27, 2020 Health Canada, the Canadian Institutes of Health Research (CIHR) and the Canadian Association of Research Ethics Boards (CAREB-ACCER) published a “Joint Statement on Clinical Trial Oversight in Canada” in response to the COVID-19 pandemic and the need to prioritize both Health Canada and REB review of COVID-19 clinical trials.  In addition, initial discussions between Health Canada, CIHR, the Secretariat on the Responsible Conduct of Research (SRCR), CAREB-ACCER and various Provincial/Territorial representatives explored ways to facilitate COVID-19 clinical trial review and implementation.
Since this time, Health Canada has launched and leads a series of engagement sessions to bring together policy-makers, regulators, funders and oversight bodies (including REBs) on clinical trials (oversight and implementation) in the context of COVID-19.
The 3rd engagement session in this series is scheduled for September 10, 2020 (1:30pm – 3:30pm EST) and will include a panel discussion entitled “COVID-19 Clinical Trial Review and Oversight: Experiences of Canadian REBs” that will cover the following areas:

  • Approval of alternate consent practices (other than written informed consent)
  • Implementing flexibility for different types of Qualified Investigators
  • Other Interim Order flexibilities REBs have had experience with


If you/your REB has experience reviewing COVID-19 clinical trials involving alternate approaches authorized under the Health Canada Clinical Trials Interim Order and you are interested in sharing your experiences as a panelist during the 3rd Health Canada Engagement Session on Clinical Trial Oversight and implementation in the Context of COVID-19 being held on September 10, 2020 please email Delilah Ofosu-Barko, President CAREB-ACCER at

Deadline: end of business day on Wednesday September 2, 2020.
Panelists will receive a table of Benefits and Flexibilities as prepared by Health Canada to support the discussion.